Navigation Links
Adventrx To Develop ANX-188 For Complications Of Arterial Disease
Date:2/28/2013

160; Near-term goals include seeking orphan drug designation for ANX-188 in ALI, meeting with FDA to discuss our development plan in ALI and, assuming FDA agrees with the plan, initiating a phase 2, clinical proof-of-concept study in late 2013 or early 2014.  Currently, we estimate that third-party costs to conduct this study will be approximately $2 million and that it will take approximately 15 to 18 months to enroll.  Ultimately, we plan to leverage the data in ALI to find a partner to develop ANX-188 in larger indications within arterial disease, such as stroke." 

Conference Call Information
The Company will hold a conference call tomorrow, Friday, March 1, 2013, at 8:30 a.m. (ET), 5:30 a.m. (PT) to discuss its development plans in acute limb ischemia.  Interested parties may access the conference call by dialing (800) 860-2442 from the U.S. and (412) 858-4600 from outside the U.S. and should request the ADVENTRX Pharmaceuticals Update Call. The webcast will be available live via the Internet by accessing the Events & Presentations page of Investors section of ADVENTRX's website at http://www.adventrx.com/investors/events/. Replays of the webcast will be available on the Company's website for 30 days and a phone replay will be available through March 6, 2013 by dialing (877) 344-7529 from the U.S. and (412) 317-0088 from outside the U.S. and entering conference reference number 10025903. 

About ADVENTRX Pharmaceuticals
ADVENTRX Pharmaceuticals is a publicly traded biopharmaceutical company headquartered in San Diego, CA.  The Company is leveraging the MAST (Molecular Adhesion and Sealant Technology) platform, derived from over two decades of clinical, nonclinical and manufacturing experience with purified and non-purified poloxamers, to develop ANX-188, its lead product candidate, for serious or life-threatening disea
'/>"/>

SOURCE ADVENTRX Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related medicine technology :

1. ADVENTRX Reviews Data Supporting Development Of ANX-188 In New Indications
2. ADVENTRX To Present At The Cowen And Company 33rd Annual Health Care Conference On March 4
3. ADVENTRX To Present At The 15th Annual BIO CEO & Investor Conference On February 12
4. ADVENTRX Initiates Pivotal Phase 3 Study of ANX-188
5. ADVENTRX Reports Third Quarter 2012 Financial Results
6. ADVENTRX Announces Details Of The Phase 3 Study Of ANX-188
7. ADVENTRX Announces Appointment Of Ted W. Love M.D. To Board Of Directors
8. ADVENTRX Pharmaceuticals To Present At The Rodman & Renshaw Annual Global Investment Conference On September 10
9. ADVENTRX Announces Appointment Of Chief Medical Officer
10. ADVENTRX Pharmaceuticals to Present at 1st Annual Sickle Cell Disease Therapeutics Conference
11. ADVENTRX Applauds Inclusion of Rare Diseases Provisions in the FDA Safety and Innovation Act
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/19/2013)... -- Whole-cell pertussis vaccines were more effective at protecting against ... outbreak, according to a new Kaiser Permanente study published ... DTwP, were available from the 1940s to 1990s, but ... the development of acellular pertussis vaccines, which are also ... United States had switched from whole-cell to ...
(Date:5/18/2013)... -- Although colonoscopy exams prevent many colon cancer deaths ... for detecting colorectal cancers 2 , the procedure is ... EndoChoice ® Inc. today unveiled research that shows ... of this procedure and greatly reduces the number of ... clinical trial results and featuring the Fuse system that ...
(Date:5/18/2013)... 18, 2013 Faruqi & Faruqi, LLP, ... potential securities fraud at AVEO Pharmaceuticals, Inc. ("AVEO" ... http://photos.prnewswire.com/prnh/20120119/MM38856LOGO ) The investigation ... violated federal securities laws by issuing materially false ... drug trials for Tivopath (tivozanib) (titled "TIVO-1").  Specifically, ...
Breaking Medicine Technology:Study Shows Whole-Cell Vaccine was More Effective than Acellular Vaccine During California Pertussis Outbreak 2Study Shows Whole-Cell Vaccine was More Effective than Acellular Vaccine During California Pertussis Outbreak 3Study Shows Whole-Cell Vaccine was More Effective than Acellular Vaccine During California Pertussis Outbreak 4New Study Shows Full Spectrum Endoscopy Procedure Reduces The 'Miss Rate' of Adenomas During Colonoscopy 2New Study Shows Full Spectrum Endoscopy Procedure Reduces The 'Miss Rate' of Adenomas During Colonoscopy 3Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $100,000 Investing In AVEO Pharmaceuticals, Inc. To Contact The Firm 2
... 26, 2007 - Aeolus,Pharmaceuticals, Inc. (OTCBB:AOLS) announced ... issue of the Journal of Neuroscience a ... and National Jewish,Medical and Research Center demonstrating ... AEOL 11207, demonstrated,neuroprotection in an animal model ...
... adding Diovan to conventional therapy , , , Study ... , , BASEL,Switzerland, April 27, 2007 ... published today in The Lancet[1], show that,adding the blood ... 39% reduction in,cardiovascular events and a 40% reduction in ...
Cached Medicine Technology:Study Demonstrating Aeolus Compound's Neuroprotection in,Parkinson's Disease Published in the Journal of Neuroscience 2Study Demonstrating Aeolus Compound's Neuroprotection in,Parkinson's Disease Published in the Journal of Neuroscience 3Diovan Achieved 40% Reduction in Stroke and Cardiovascular Events,in Landmark Jikei Heart Study 2Diovan Achieved 40% Reduction in Stroke and Cardiovascular Events,in Landmark Jikei Heart Study 3Diovan Achieved 40% Reduction in Stroke and Cardiovascular Events,in Landmark Jikei Heart Study 4Diovan Achieved 40% Reduction in Stroke and Cardiovascular Events,in Landmark Jikei Heart Study 5Diovan Achieved 40% Reduction in Stroke and Cardiovascular Events,in Landmark Jikei Heart Study 6Diovan Achieved 40% Reduction in Stroke and Cardiovascular Events,in Landmark Jikei Heart Study 7
(Date:5/20/2013)... Adeptia Inc., a leading ... process integration solutions, today announced the availability ... solution. Version 6.0 is the only ... business processes involving data access, validation, transformation, ... interaction for real-time decision-making and exception-handling. The ...
(Date:5/20/2013)... Although many hospital intensive care units have a ... outcomes, new research suggests this may have no ... teaching hospitals in the United States and three-quarters ... in the ICU, the practice may unnecessarily increase ... with fewer resources, the study authors said. ...
(Date:5/20/2013)... NY (PRWEB) May 20, 2013 In ... of the numerous scientific accomplishments achieved at The ... group of female scientists, Advancing Women in Science ... breakfast on May 17. Scientists, educators, business and ... celebrate excellence and achievements of women in science. ...
(Date:5/20/2013)... toothpaste that transforms the sweet flavor of orange juice ... mysterious sensory phenomenon in colorful, animated detail ... award-winning Bytesize Science video series at ... scientific society, explains that the mainstay ingredients in toothpaste ... for short. When you brush your teeth, SLS produces ...
(Date:5/20/2013)... 2013) Wolters Kluwer Health is ... Wilkins (LWW) published journals won 13 ASHPE awards ... member articles and publications for editorial, design, print ... honor to be recognized year after year for ... the industry with quality, depth, and impact," said ...
Breaking Medicine News(10 mins):Health News:Adeptia Announces New Release of Enterprise Business Integration Solution 2Health News:Adeptia Announces New Release of Enterprise Business Integration Solution 3Health News:Nighttime Docs at ICUs Don't Boost Patient Outcomes: Study 2Health News:North Shore-LIJ's Feinstein Institute Celebrates Women in Science During National Women’s Health Week 2Health News:North Shore-LIJ's Feinstein Institute Celebrates Women in Science During National Women’s Health Week 3Health News:Wolters Kluwer Health receives 13 awards from the ASHPE 2
... of Charity Health System Bargaining in Bad Faith, ... operated throughout California by the Daughters of,Charity Health System ... Caregivers represented by SEIU United Healthcare Workers-West have been,bargaining ... But,management has refused to make any economic proposals, and ...
... WAKEFIELD, MA, Aug. 15 /PRNewswire-FirstCall/ - NUCRYST,Pharmaceuticals, a ... and inflammation, today announced that on August 14, ... stating that, for the last,30 consecutive trading days, ... market value of publicly held shares ("MVPHS") of ...
... YORK, Aug. 15 The Hereditary Disease Foundation,(HDF) ... Administration has,approved Xenazine, or tetrabenazine, for the treatment ... a major cause of disability and death in ... mere inconvenience; it can,prevent Huntington,s disease patients from ...
... Food and Drug Administration today approved tetrabenazine, the first ... treat Huntington,s disease, a fatal, inherited neurodegenerative disorder for ... eight months after an advisory panel unanimously voted to ... the disease. , The drug is already widely used ...
... in a dangerously abnormal way, a series of death signals ... research to appear in the August 15 issue of ... a way in mice to amplify the signals that tell ... that normally helps cells to avoid self-destruction. , The work, ...
... , ... London, UK (PRWEB) August 15, 2008 -- X Factor star and mother of ... [MYA Cosmetic Surgery]. The 36 year old, who is well known ... MYA and in total has lost 6 inches from her waist, 4 inches ...
Cached Medicine News:Health News:NUCRYST Receives Deficiency Notice from NASDAQ 2Health News:NUCRYST Receives Deficiency Notice from NASDAQ 3Health News:FDA approves first drug for Huntington's disease 2Health News:FDA approves first drug for Huntington's disease 3Health News:FDA approves first drug for Huntington's disease 4Health News:By amplifying cell death signals, scientists make precancerous cells self-destruct 2Health News:X Factor's Niki Evans Amazing Cosmetic Surgery Success 2Health News:X Factor's Niki Evans Amazing Cosmetic Surgery Success 3
... optimize the accuracy and precision of Finnpipettes. ... widely recognized by customers throughout the world. ... the years and now covers a full ... filter tips, certified pure tips, stepper tips ...
... Finntips have been designed to optimize the ... of our tip products is widely recognized ... range has been extended over the years ... standard and special tips including filter tips, ...
... when presented in convenient, steady, Tipack ... pick up directly from the rack. ... tips are loaded without manual intervention. ... security sticker. Fully autoclavable, Tipacks are ...
... Finntips have been designed to optimize ... quality of our tip products is widely ... Finntip range has been extended over the ... of standard and special tips including filter ...
Medicine Products: